GANX Stock Analysis
GA
Uncovered
Gain Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2021-03-18. The company uses its platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover allosteric sites to modulate protein and identify small molecules that bind these sites to modulate protein function, and treat the underlying cause of the disease. Its pipeline includes its Structurally Targeted Allosteric Regulators (STARs), which develop a pipeline of small molecule drug candidates to address complex diseases. The company is evaluating the STARs for the treatment of Gaucher and Parkinson's disease in neuronal cells derived induced pluripotent stem cells (iPSCs) of a patient with Gaucher disease that contained the disease-causing mutation of the GBA1 gene and from iPSCs of a healthy donor with a normal GBA1 gene.